Algorithmic Biologics
Algorithmic Biologics builds programmable diagnostics using molecular computing (nucleic acid and protein logic gates) in place of silicon. The Bangalore-based company serves enterprise customers in healthcare, pharma, and agriculture through its Sequence Transduction and Tapestry platforms and an AI-powered assay design system.
- Company typePrivate
- Founded2020
- HeadquartersBangalore, India
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Algorithmic Biologics does
Algorithmic Biologics is a molecular computing company that builds programmable diagnostics infrastructure using purified nucleic acid and protein molecules as logic gates in place of silicon-based circuits. Founded around 2020-2021, the company is headquartered in Bangalore, India, with a US office in Lewes, Delaware, and operates with a team of approximately 15 employees. The platform applies 20+ years of academic research from its founder, Manoj Gopalkrishnan, a recognized leader in the field, to construct chemical computation systems for molecular diagnostics. The technology is protected by 8 patents across 5 jurisdictions and is supported by an AI-powered assay design capability that performs in-silico design prior to wet-lab testing.
The commercial product portfolio centers on two platforms: Sequence Transduction, which converts DNA/RNA targets into programmable proxy sequences, and Tapestry, a sparse-recovery-enabled multiplexing platform that enables sample pooling at scale. A third product, Transcriptomics, is in development. Target end markets include healthcare, pharmaceuticals, agriculture, reproductive health, cancer screening, and sepsis diagnostics. GTM is enterprise-direct with event-driven conference presence and an emphasis on strategic partnerships; the company has assembled a network of 18+ undisclosed healthcare and pharmaceutical partners and collaborators.
Revenue mechanics operate through three B2B channels: platform licensing, assay development services (professional services), and technology partnerships (managed services). Specific contract values and pricing are not publicly disclosed. The company has raised capital across three disclosed events — a January 2022 seed from Axilor Ventures, a July 2023 round from Google for Startups, and a February 2024 $2.49 million round led by Bharat Innovation Fund with participation from Axilor Ventures — for an aggregate disclosed funding base of approximately $2.5 million.
Algorithmic Biologics firmographics
Firmographics- Name
- Algorithmic Biologics
- Legal name
- Algorithmic Biologics
- Website
- https://algorithmicbiologics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Algorithmic Biologics builds programmable diagnostics using molecular computing (nucleic acid and protein logic gates) in place of silicon. The Bangalore-based company serves enterprise customers in healthcare, pharma, and agriculture through its Sequence Transduction and Tapestry platforms and an AI-powered assay design system.
- Ownership category
- akta.pro rank
Algorithmic Biologics industry classification
Industry- Product category
- Molecular Diagnostics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Algorithmic Biologics is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Algorithmic Biologics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing: Licensing of proprietary molecular computing platforms (Sequence Transduction and Tapestry) to diagnostic and pharmaceutical companies for assay development. Enables reusable detection chemistry and programmable assay design.
- Assay Development Services: Custom assay development partnerships with healthcare, pharmaceutical, and agricultural companies using the company's AI-powered platform. The company collaborates with 18+ partners on precision diagnostics solutions.
- Technology Partnership: Strategic partnerships for co-development of molecular diagnostics, including companion diagnostics, cancer diagnostics, infectious disease screening, and reproductive genetics applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Algorithmic Biologics product offering
Product offeringCore offering
Algorithmic Biologics develops an AI-powered molecular computing platform that dramatically accelerates multiplexed assay design for diagnostics and research. Its two core products — Sequence Transduction (a compression architecture converting DNA/RNA targets into programmable proxy sequences) and Tapestry (sparse-recovery-enabled sample pooling with algorithmic decoding) — enable assay development in 3 months versus the 18-month industry standard, support 500+ targets in a single multiplexed assay, and integrate with existing qPCR/dPCR infrastructure without new capital expenditure.
Product overview
Algorithmic Biologics offers an AI-powered molecular computing platform with two core products: Sequence Transduction and Tapestry, plus an upcoming Transcriptomics module. Sequence Transduction is a compression architecture that converts DNA/RNA targets into programmable proxy sequences for ultra-rapid multiplexed assay development (under 4 months vs. traditional 18 months). Tapestry provides sparse-recovery-enabled multiplexing for sample pooling and algorithmic decoding. The platform is designed for universal detection chemistry reuse and supports 500+ targets in a single multiplexed assay. Applications span cancer diagnostics, companion diagnostics, infectious disease screening, reproductive genetics, rare disease screening, and population-scale surveillance.
Differentiator
Problem solved
Functional benefit
Products and services
- Sequence Transduction
Quantifiable outcome
- Assay development time reduced from 18 months to 3 months
- +4 more outcomes
Companies that use Algorithmic Biologics
Customer profileNamed customers2 records
Segments6 records
Ideal customer profiles3 records
Algorithmic Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Algorithmic Biologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Healthcare and Pharma Partnerscore18+ industry partners and collaborators using the platform for precision diagnostics solutions. Partners span healthcare, pharmaceutical, and agricultural applications. The company actively seeks new partnerships for assay development collaboration.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Algorithmic Biologics competitors and assessment
Company assessmentDirect peers
- DNAnexus: Cloud-based bioinformatics and genomics data platform serving pharma, diagnostics, and clinical labs. Directly comparable to Algorithmic Biologics as a software/informatics layer that sits on top of sequencing and molecular assay workflows, enabling researchers to design, run, and analyze complex genomic tests.
- Benchling: Cloud platform for life science R&D including ELN, molecular biology design tools, and registry capabilities. Comparable as a software platform that helps scientists design DNA/RNA constructs and assays, with overlapping buyer (biopharma R&D, synthetic biology) and overlapping AI/ML roadmap for biological design.
- Twist Bioscience: DNA synthesis and synthetic biology company offering custom oligonucleotides, NGS target enrichment panels, and antibody libraries. Comparable to Algorithmic Biologics as a deep-tech platform that programmatically designs and produces biological molecules for diagnostics and research customers.
Emerging players
- Insitro: AI/ML-driven drug discovery platform combining high-throughput biology with machine learning. Comparable as a venture-backed deep-tech company applying AI to biological experiment design and assay optimization, with overlapping therapeutic-area ambitions.
- Schrödinger: Computational chemistry and physics-based simulation platform for drug and materials discovery. Comparable as a software-first life sciences platform that uses computation to dramatically reduce experimental cycles, with similar value proposition of compressing wet-lab iteration timelines.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable as a deep-tech platform using algorithms and automation to industrialize biological experimentation, though focused on therapeutics rather than diagnostics assay design.
- AbCellera Biologics: AI-powered antibody discovery platform integrating microfluidics, genomics, and machine learning. Comparable as a deep-tech, venture-backed platform that uses computation plus high-throughput biology to industrialize biologic discovery for pharma partners, with similar go-to-market motions.
Broad incumbents
- Ginkgo Bioworks: Synthetic biology platform company engineering organisms for industrial and healthcare applications. Comparable as a programmatic biology platform serving multiple verticals, though operating at much larger scale and broader scope than Algorithmic Biologics.
- 10x Genomics: Provider of instruments, consumables, and software for single-cell and spatial genomics. Comparable as a molecular biology tools company whose platform sits at the intersection of novel assay chemistry, computational decoding, and life science customer workflows.
- Bio-Rad Laboratories: Major life science research and clinical diagnostics company with leadership in digital PCR and qPCR. Comparable because AlgoBio's platform is explicitly designed to drop into Bio-Rad-style dPCR/qPCR workflows, making Bio-Rad both a potential channel partner and a competitive incumbent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Algorithmic Biologics social profiles
Digital presenceAlgorithmic Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algorithmic Biologics leadership team
Management profileNumber of profiles
Profiles11 records
Algorithmic Biologics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algorithmic Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algorithmic Biologics
What does Algorithmic Biologics do?
Algorithmic Biologics develops an AI-powered molecular computing platform that dramatically accelerates multiplexed assay design for diagnostics and research. Its two core products — Sequence Transduction (a compression architecture converting DNA/RNA targets into programmable proxy sequences) and Tapestry (sparse-recovery-enabled sample pooling with algorithmic decoding) — enable assay development in 3 months versus the 18-month industry standard, support 500+ targets in a single multiplexed assay, and integrate with existing qPCR/dPCR infrastructure without new capital expenditure.
Is Algorithmic Biologics a public or private company?
Algorithmic Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Algorithmic Biologics founded?
Algorithmic Biologics was founded in 2020. It employs 11 to 50 people.
Where is Algorithmic Biologics based?
Algorithmic Biologics is headquartered in Bangalore, India, in the Asia region.
How does Algorithmic Biologics make money?
Three revenue lines are on record. Platform Licensing is the primary driver. The others are assay Development Services and technology Partnership.
Who are Algorithmic Biologics's main competitors?
Direct peers on record are DNAnexus, Benchling and Twist Bioscience. Emerging players are Insitro, Schrödinger, Recursion Pharmaceuticals and AbCellera Biologics. Broad incumbents are Ginkgo Bioworks, 10x Genomics and Bio-Rad Laboratories.
Does Algorithmic Biologics have an API?
No public API is recorded for Algorithmic Biologics.
What industry is Algorithmic Biologics in?
Algorithmic Biologics's product category is Molecular Diagnostics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 541714 and its SIC code is 3826.